Parallel Advisors’s Arbutus Biopharma ABUS Stock Holding History

Parallel Advisors’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.99K	Hold	1,039	–	–	﹤0.01%	3210
2026 Q1	$4.68K	Sell	1,039 -165	-14%	-$721	﹤0.01%	3054
2025 Q4	$5.79K	Hold	1,204	–	–	﹤0.01%	2794
2025 Q3	$5.47K	Sell	1,204 -116	-9%	-$426	﹤0.01%	2744
2025 Q2	$4.08K	Buy	1,320 +489	+59%	+$1.62K	﹤0.01%	2809
2025 Q1	$2.9K	Hold	831	–	–	﹤0.01%	2866
2024 Q4	$2.72K	Hold	831	–	–	﹤0.01%	2862
2024 Q3	$3.2K	Hold	831	–	–	﹤0.01%	2761
2024 Q2	$2.57K	Buy	831 +281	+51%	+$843	﹤0.01%	2734
2024 Q1	$1.42K	Hold	550	–	–	﹤0.01%	2873
2023 Q4	$1.38K	Hold	550	–	–	﹤0.01%	2876
2023 Q3	$1.12K	Hold	550	–	–	﹤0.01%	2957
2023 Q2	$1.26K	Sell	550 -122	-18%	-$318	﹤0.01%	2873
2023 Q1	$2.04K	Buy	672 +122	+22%	+$344	﹤0.01%	2770
2022 Q4	$1.28K	Hold	550	–	–	﹤0.01%	2837
2022 Q3	$1K	Sell	550 -169	-24%	-$398	﹤0.01%	2827
2022 Q2	$2K	Buy	719 +169	+31%	+$433	﹤0.01%	2521
2022 Q1	$2K	Hold	550	–	–	﹤0.01%	2535
2021 Q4	$2K	Hold	550	–	–	﹤0.01%	2644
2021 Q3	$2K	Hold	550	–	–	﹤0.01%	2630
2021 Q2	$2K	Hold	550	–	–	﹤0.01%	2516
2021 Q1	$2K	Hold	550	–	–	﹤0.01%	2433
2020 Q4	$2K	Hold	550	–	–	﹤0.01%	2254
2020 Q3	$2K	Buy	+550	New	+$1.67K	﹤0.01%	2253

Other funds holding ABUS

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

WCM

Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Parallel Advisors's ABUS Position: Q2 2026 in Review

Parallel Advisors held its Arbutus Biopharma (ABUS) position steady in Q2 2026 at 1,039 shares worth $4.99K. The position accounts for ﹤0.01% of the portfolio, ranked #3210.

Parallel Advisors first reported a position in ABUS in Q3 2020 and has held it in 24 quarters since. The position peaked at $5.79K in Q4 2025. 176 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

Parallel Advisors held 1,039 shares of Arbutus Biopharma worth $4.99K as of Q2 2026.
Parallel Advisors left its Arbutus Biopharma share count unchanged in Q2 2026.
Arbutus Biopharma made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3210 holding.
Parallel Advisors first reported a position in Arbutus Biopharma in Q3 2020 and has held it in 24 quarters since.
Parallel Advisors's Arbutus Biopharma position peaked at $5.79K in Q4 2025.
176 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.